Blockchain Registration Transaction Record

Lantern Pharma Gets Taiwan IRB Nod for Phase 2 HARMONIC Trial

Lantern Pharma receives Taiwan IRB approval for Phase 2 HARMONIC trial of LP-300 in EGFR L858R lung cancer, expanding clinical development.

This news matters because it marks a critical expansion of Lantern Pharma's clinical program into Taiwan, a region with a high incidence of EGFR-mutated lung cancer. By opening Part 2 of the HARMONIC trial, Lantern is accelerating the development of LP-300, a potential therapy for patients with the EGFR exon 21 L858R mutation who have progressed after tyrosine kinase inhibitor treatment—a population with significant unmet need. The preliminary data, though early, suggest a meaningful progression-free survival benefit, and the protocol amendment to allow eight cycles could further enhance efficacy. For investors, this progress demonstrates Lantern's ability to execute on its AI-driven precision oncology strategy and could bring it closer to regulatory submission. For patients, it offers hope for a new treatment option in a difficult-to-treat cancer subtype.